TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

In recent years, chimeric antigen receptor-modified T cell (CAR T cell) therapy has proven to be a promising approach against cancer. Nonetheless, this approach still faces multiple challenges in eliminating solid tumors, one of which being the immunosuppressive tumor microenvironment (TME). Here, w...

Ausführliche Beschreibung